검색으로 10,000+ 프로그램 중 최대 5개를 골라 PK/PD · 독성 · 임상을 나란히 비교합니다. · 다음 갱신 D-13 · 마지막 7월 13일
현재 선택: 1개
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | Recombinant Interferon Alfa (Recombinant Interferon Alfa) SPP Pharmaclon Ltd.·Bladder Cancer ORR 32.4%·t½ 57 h |
|---|---|
Overview Program | Recombinant Interferon Alfa |
Overview Company | SPP Pharmaclon Ltd. |
Overview Modality | CGT |
Overview Target | Bladder Cancer |
Overview Indication | Colorectal Cancer; Kidney Cancer |
Overview Phase | PHASE_2 |
Overview Status | ACTIVE |
MoA Mechanism | targets TIM3 on exhausted TILs and activates DCs via the IFNAR receptor |
MoA Biomarker | biomarkers for HBsAg clearance and responses to Peg-IFN-α in HBeAg-negative chronic hepatitis B patient |
PK/PD Half-life | 57 h |
PK/PD Species | Mouse |
PK/PD Animal (cat.) | Mouse |
PK/PD Experiment | Pharmacokinetic |
Toxicology Species | Mouse |
Toxicology Animal (cat.) | Mouse |
Toxicology Major finding | Pharmacokinetics and Pharmacodynamics of Ropeginterferon Alfa-2b in Healthy Japanese and Caucasian Subjects After Single Subcutaneous Administration.. Ropeginterferon alfa-2b is a novel monopegylated recombinant interferon alfa-2b for the treatment of patients with polycythemia vera. The objectives of this study were to evaluate the pharmacokinetics, pharmacodynamics, safety, and tolerability of r… |
Toxicology CRS | Reported |
Clinical Primary efficacy | ORR 32.4% |
Clinical ORR | 32.4% |
Clinical Result source | ClinicalTrials.gov NCT00738530 |
Clinical Data Tier / Score | A · 42 |
Clinical Program phase | PHASE_2 |
Clinical Clinical sync | 2026년 7월 12일 (1일 전) |
검색으로 10,000+ 프로그램 중 최대 5개를 골라 PK/PD · 독성 · 임상을 나란히 비교합니다. · 다음 갱신 D-13 · 마지막 7월 13일
현재 선택: 1개
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | Recombinant Interferon Alfa (Recombinant Interferon Alfa) SPP Pharmaclon Ltd.·Bladder Cancer ORR 32.4%·t½ 57 h |
|---|---|
Overview Program | Recombinant Interferon Alfa |
Overview Company | SPP Pharmaclon Ltd. |
Overview Modality | CGT |
Overview Target | Bladder Cancer |
Overview Indication | Colorectal Cancer; Kidney Cancer |
Overview Phase | PHASE_2 |
Overview Status | ACTIVE |
MoA Mechanism | targets TIM3 on exhausted TILs and activates DCs via the IFNAR receptor |
MoA Biomarker | biomarkers for HBsAg clearance and responses to Peg-IFN-α in HBeAg-negative chronic hepatitis B patient |
PK/PD Half-life | 57 h |
PK/PD Species | Mouse |
PK/PD Animal (cat.) | Mouse |
PK/PD Experiment | Pharmacokinetic |
Toxicology Species | Mouse |
Toxicology Animal (cat.) | Mouse |
Toxicology Major finding | Pharmacokinetics and Pharmacodynamics of Ropeginterferon Alfa-2b in Healthy Japanese and Caucasian Subjects After Single Subcutaneous Administration.. Ropeginterferon alfa-2b is a novel monopegylated recombinant interferon alfa-2b for the treatment of patients with polycythemia vera. The objectives of this study were to evaluate the pharmacokinetics, pharmacodynamics, safety, and tolerability of r… |
Toxicology CRS | Reported |
Clinical Primary efficacy | ORR 32.4% |
Clinical ORR | 32.4% |
Clinical Result source | ClinicalTrials.gov NCT00738530 |
Clinical Data Tier / Score | A · 42 |
Clinical Program phase | PHASE_2 |
Clinical Clinical sync | 2026년 7월 12일 (1일 전) |
추천 비교
추천 비교